JEUNESSE GLOBAL- Laura Jensen Your Consultant
JEUNESSE Global is a skincare company offering much more than any other company and here is why: Dr. Nathan Newman has a patent-pending formula using ADULT STEM CELLS which are the ...
By: Laura Jensen
Excerpt from:
JEUNESSE GLOBAL- Laura Jensen Your Consultant - Video
Boston, MA (PRWEB) January 29, 2015
Dr. James Sherley, Director of the new biotech start-up Asymmetrex, LLC (formerly known as The Adult Stem Cell Technology Center, LLC) is looking forward to four upcoming opportunities in 2015 to continue to impress both academic and industry audiences with his companys very frank take on what is needed to accelerate progress in stem cell medicine.
Asymmetrex has set the focus for its efforts on adult stem cells that are found in the organs and tissues of children and adults. Unlike human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), adult stem cells are free of induced mutations, are not tumor-forming, and have the essential ability to continuously regenerate mature human tissue cells like those in children and adults. To date, hESCs and iPSCs have only been able to regenerate immature cells, and even those not continuously.
Previously, the two main challenges hindering wider use of adult stem cells for drug development and medical therapies have been difficulty producing them and difficulty counting them. Asymmetrex has reported, and in many cases secured patents for, new technologies that reduce or eliminate both of these challenges. At the coming conferences, Dr. Sherley will describe the companys most recent technological advances in this regard and discuss the science that led to them.
In particular, he will highlight the companys newest technology developed with partner AlphaSTAR Corporation for estimating adult stem cell number in any human tissue. The two companies are developing the new technology as an assay to detect drug candidates that will fail in expensive pre-clinical animal studies and clinical trials because of intolerable toxicity against tissue stem cells. By screening-out such drugs earlier in the drug development process, Asymmetrex and AlphaSTAR estimate that together they could save the U.S. pharmaceutical industry $4-5 billion each year.
The four scheduled conferences include the 7th Annual Predictive Toxicology Summit, February 16-18, in London; the 5th World Congress on Cell and Stem Cell Research, March 23-25, in Chicago; the 2015 Annual Meeting at Experimental Biology, March 28-April 1, in Boston; and the Inaugural 3D Cellular Models Conference, June 11-12, also in Boston.
The breadth of conference topics reflects the many important roles that adult tissue stem cells play in human biology and cellular medicine. Dr. Sherley offers that, Because of the importance of adult stem cells in normal body function, it is not surprising that Asymmetrexs technologies impact so many different facets of stem cell biology, regenerative medicine, and drug development.
About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.
See more here:
Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult ...
MIAMI (PRWEB) January 29, 2015
Regenestem Network, the worlds largest membership network of regenerative medicine practitioners, has announced the launch of a new stem cell clinic in Oaxaca, Mexico. The new facility, offering the most advanced cellular medicine protocols and techniques available is in partnership with Ulises Cervera, M.D. a neurologist coming from the Children's Hospital of Morelia, Mexico.
The new Oaxaca facility will offer the most advanced protocols and techniques available in stem cell medicine to patients from across Mexico and around the world.
Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner.
In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.
Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.
Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.
The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.
For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.
About Regenestem: Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.
View original post here:
Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in ...
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr.PV Mahajan
Patient testimonial of Limb Girdle Muscular Dystrophy treated by StemRx Bioscience Solutions Pvt. Ltd.
By: StemRx BioScience
Read the original here:
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr.PV Mahajan - Video
Stem Cell Therapy + PRP Helps Shoulder Injury and Whiplash Patient - Denise Lawson
Denise Lawson experienced two motor vehicle accidents in 2001 that left her with neck pain, headaches, and sporadic episodes of weakness on the left side of her body. Over time, Denise developed...
By: StemCell ARTS
Read more:
Stem Cell Therapy + PRP Helps Shoulder Injury and Whiplash Patient - Denise Lawson - Video
Talking Clinical Trials and Stem Cells With One Of Mexico #39;s
Talking Clinical Trials and Stem Cells With One Of Mexico #39;s Best Physicians http://www.theclinicaltrials.guru.
By: Dan Sfera
Go here to read the rest:
Talking Clinical Trials and Stem Cells With One Of Mexico's - Video
Continuous-Flow Sorting of Stem Cells and Differentiation Products based on Dielectrophoresis
Video related to research article appearing in Lab on a Chip. Yi Wang et al., "Continuous-Flow Sorting of Stem Cells and Differentiation Products based on Dielectrophoresis". Read the article...
By: labonachipVideos
See the original post here:
Continuous-Flow Sorting of Stem Cells and Differentiation Products based on Dielectrophoresis - Video
Arthritic knees three months after bone marrow stem cell therapy by Harry Adelson, N.D.
Holly, three-time World Cup Downhill Gold Medalist and Olympian, discusses her outcome from bone marrow stem cells for her arthritic knees performed at Docere Clinics http://www.docereclinics.com.
By: Harry Adelson, N.D.
See the original post:
Arthritic knees three months after bone marrow stem cell therapy by Harry Adelson, N.D. - Video
Functional Medicine Minute - Vitamin D Stops Breast Cancer Stem Cells In Their Tracks
Do you fear breast cancer? Does breast cancer run in your family? Would you be interested in a evidence-based way to prevent breast cancer? Dr. John Bartemus...
By: Dr. John Bartemus
See the original post here:
Functional Medicine Minute - Vitamin D Stops Breast Cancer Stem Cells In Their Tracks - Video
Bone stem cells shown to regenerate bone and cartilage in adult mice
A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. Further study could provide greater understanding of ...
By: Columbia University Medical Center
Continued here:
Bone stem cells shown to regenerate bone and cartilage in adult mice - Video
20150124 , Success in skin cells cultured neural stem cells.
.
By: byung jue Kim
See the original post here:
20150124 , Success in skin cells cultured neural stem cells. - Video
NEUROSTEM Action Mechanism
NEUROSTEM is a drug based on mesenchymal stem cells derived from allogeneic umbilical cord blood that is being developed to treat Alzheimer #39;s type dementia. The drug is currently undergoing...
By: Medipost
Originally posted here:
NEUROSTEM Action Mechanism - Video
IMAGE:CDK6 is needed for leukemic stem cell activation (left). When CDK6 is absent, the LSC remains in a quiescent state and leukemia formation is prohibited (right). view more
Credit: Angelika Berger / Vetmeduni Vienna
Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has given a tantalizing clue to a solution. In the current issue of Blood, the scientists report that the cell-cycle kinase CDK6 is required for activation of the stem cells responsible for causing leukemia.
Hematopoietic stem cells (HSCs) are normally inactive, i.e. quiescent. When new blood cells are needed, for example to replace blood that has been lost, HSCs start to multiply and develop into mature blood cells. If the process is initiated at an inappropriate time, hematopoietic diseases such as leukemia may result and leukemic stem cells may develop. These represent a major challenge to leukemia therapy: they are quiescent and thus protected from elimination by the immune system and from treatment such as chemotherapy. Leukemic stem cells frequently cause relapse in cancer patients, often years or even decades after an apparently successful treatment.
Working with stem cells isolated from mice, Ruth Scheicher and colleagues at the University of Veterinary Medicine, Vienna have investigated possible differences between leukemic stem cells and the healthy stem cells in the body. They looked in particular at the function of the CDK6 protein, which is known to be involved in controlling the cell cycle. Surprisingly, CDK6 was also found to regulate the activation of hematopoietic and leukemic stem cells, which it does by inhibiting the transcription factor Egr1. Upon loss of CDK6, Egr1 becomes active and prevents stem cells from dividing. In a further twist to the tale, the mechanism operates only when hematopoietic stem cells are stressed, e.g. in leukemia, and not in the normal physiological situation.
Scheicher is quick to note the significance of her finding. "CDK6 is absolutely necessary for leukemic stem cells to induce disease but plays no part in normal hematopoiesis. We thus have a novel opportunity to target leukemia at its origin. Inhibiting CDK6 should attack leukemic stem cells while leaving healthy HSCs unaffected".
###
Service: The article 'CDK6 as a key regulator of hematopoietic and leukemic stem cell activation' by Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zchbauer-Mller S, Zuber J, Malumbres M, Kollmann K and Sexl V. was published in the journal Blood. http://www.bloodjournal.org/content/125/1/90.long?sso-checked=true
About the University of Veterinary Medicine, Vienna
The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. http://www.vetmeduni.ac.at
Read more:
Keeping the Kraken asleep
Pluripotent stem cells are cells capable of indefinite expansion and then differentiation into any and all of the cell types of the human body. Examples of pluripotent stem cells are human embryonic stem cells (hES) and induced pluripotent stem (iPS) cells. These stem cells potentially offer a new technology platform for the manufacture of a wide array of cell types designed to be transplanted into the body to restore healthy tissue function.
BioTime and its subsidiaries are focused on developing and commercializing a broad portfolio of innovative cellular therapeutics and diagnostic products, while also continuing to build value in other ways, such as through the addition of new patents to our industry-leading intellectual property estate, said Dr. Michael D. West, Ph.D., BioTimes Chief Executive Officer. We are making significant strides in patenting our core platform of pluripotent stem cell technology and strengthening our competitive position in regenerative medicine. For the first time in history, pluripotent stem cells offer a means of manufacturing previously rare and valuable human cell types in a cost-effective manner and on an industrial scale. We plan to utilize our strengthened patent position to drive value for our shareholders as the field of regenerative medicine begins to address the large and growing markets associated with chronic and age-related degenerative disease.
New Patents Owned by BioTime or one of its subsidiaries:
European patent 1809739 This issued patent claims cell culture media for the proliferation and scale-up of hES cells. The patent issuing in Austria, France, Germany, Ireland, Switzerland and Sweden provides a propagation medium for culturing hES cells in the laboratory such that the cells proliferate without differentiating as defined in the claims. The technology allows the user to rapidly produce high-quality embryonic stem cells for use in therapy and drug discovery, in a cost-effective and controlled manner, from defined or commercially available reagents. The patent is therefore useful for manufacturing products from hES cells. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Singapore and Hong Kong, with additional applications pending.
Canada patent 2559854 and China patent ZL200580008779.0 These patents claim a differentiation method for making high purity heart muscle preparations from pluripotent stem cells such as hES cells suitable for use in regenerative medicine. The issued claims cover methods wherein the pluripotent stem cells are treated with specific growth factors and differentiation conditions to manufacture beating heart muscle cells. The patents are therefore useful in the manufacture and commercialization of heart muscle cells for research, for the testing of drugs on the heart, and potentially for regenerating heart muscle following a heart attack or heart failure. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Japan and Singapore, with additional applications pending.
South Korea patent1543500B The patent titled, Hematopoietic Cells from Human Embryonic Stem Cells, claims methods for using pluripotent stem cell technology for inducing immune tolerance of cells transplanted into a patient (that is, in helping to prevent the rejection of transplanted cells). As such, the patent claims may be useful in commercializing diverse types of transplantable cells. Patents in the same family have previously issued in Australia, UK, Israel, Japan and Singapore, with additional applications pending.
Canada patent 2468335 The patent describes cartilage-forming cells derived from human pluripotent stem cells such as hES cells. The claims in the patent relate to a system of making the cartilage-forming cells using factors of the transforming growth factor beta (TGF-beta) family, of immortalizing the cells with the human telomerase gene, pharmaceutical formulations of the cells for therapeutic use in arthritis, as well as other claims. The patent is therefore useful for the manufacture of such cells for use in research and potentially in therapy for a number of applications in orthopedic medicine. Patents in the same family have previously issued in the United States, Australia, Singapore, Israel and South Korea, with additional applications pending.
Israel patent208116 The patent titled, Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells, claims methods for the manufacture of dendritic cells from primate pluripotent stem cells. Dendritic cells are cells that trigger an immune response to a particular molecule. Often their role is to stimulate the immune system to attack microorganisms such as bacteria. BioTimes subsidiary Asterias Biotherapeutics is developing hES cell-derived dendritic cells modified to trigger an immune response to specific antigens related to cancer. A patent in the same family has previously issued in the United States, with additional applications pending.
Singapore patent 188098 The patent titled, Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes, claims certain polymers upon which heart muscle cells derived from pluripotent stem cells may be cultured. The patent is potentially useful for the manufacture of human heart muscle cells for drug screening and toxicity testing and for use in the manufacture of such cells for transplantation into human subjects for the treatment of heart disease. A patent in the same family has previously issued in the United States, with additional applications pending.
Singapore patent 176957 The patent titled, Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes, claims methods for the purification of pluripotent stem cell-derived oligodendrocytes by the removal of contaminating cells that display an antigen called epithelial cell adhesion molecule (EpCAM). This method is potentially useful in the purification of such oligodendrocytes prior to their use in research or human therapy. Patents in the same family have previously issued in the United States and China, with additional applications pending.
Read more from the original source:
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer ...
Stem Cells Transplanted into Cancer Patient
I created this video with the YouTube Video Editor (http://www.youtube.com/editor)
By: Mind, Body Soul
The rest is here:
Stem Cells Transplanted into Cancer Patient - Video
Stem Cells - Biology - Science - Get That C In Your GCSE
A revision video to help you pass your Science GCSE. Let Mr Thornton simplify what stem cells are and why they #39;re important - it #39;s easy when you know how! No...
By: Christopher Thornton
Read the original:
Stem Cells - Biology - Science - Get That C In Your GCSE - Video
Kim Solez Intro to AI: Stem Cells Regenerative Medicine Pathology-2015 and Aibos
Dr. Kim Solez gives the introduction to the first artificial intelligence lecture, with discussion of student participation in the Pathology-2015 meeting in New Orleans, stem cell and regenerative...
By: Kim Solez
See original here:
Kim Solez Intro to AI: Stem Cells Regenerative Medicine Pathology-2015 and Aibos - Video
Sleep-apnea surgery using Stem cells post-op day 3
2conservative measures first.
By: darrell cee
See the original post:
Sleep-apnea surgery using Stem cells post-op day 3 - Video
How Do Stem Cells Work?
Board-Certified Orthopedic Surgeon Michael Price from Reverse Aging Centre Beverly Hills, explains how stem cells work.
By: Reverse Aging Centre